Ambrisentan

Ambrisentan Struktur
177036-94-1
CAS-Nr.
177036-94-1
Englisch Name:
Ambrisentan
Synonyma:
CS-135;LU 208075;BSF 208075;AMBRISENTAN;Anrisentan API;((S)-Ambrisentan);(R,S)-Ambrisentan;Ambrisentan, >=98%;Ambrisentan Tablets;(R,S)-AMbrisentan-d5
CBNumber:
CB71011125
Summenformel:
C22H22N2O4
Molgewicht:
378.42
MOL-Datei:
177036-94-1.mol

Ambrisentan Eigenschaften

Schmelzpunkt:
>150°C (dec.)
Siedepunkt:
551.1±60.0 °C(Predicted)
Dichte
1.228±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,2-8°C
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
0.97±0.10(Predicted)
Farbe
White to Off-White
Merck 
14,384

Sicherheit

R-Sätze: 62/63
S-Sätze: 53-36/37/39-45
RTECS-Nr. UA2459660
HS Code  29335990

Ambrisentan Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Ambrisentan is a selective endothelin-A (ETA) receptor antagonist introduced for the oral treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity and delay clinical worsening. It is the third ET-receptor antagonist to be marketed for this indication behind bosentan and sitaxsentan. PAH is a rare disease of the small pulmonary arteries characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and ultimately, right ventricular failure and premature death. Early symptoms of PAH include gradual onset of shortness of breath, fatigue, palpitation, edema, and fainting. Endothelin-1 (ET-1), a potent vasoconstrictor and smooth muscle mitogen, is a key contributor to the acceleration of the disease, and its effects are mediated through activation ofETA and ETB receptors.

Chemische Eigenschaften

White to Off White Solid

Verwenden

Nonpeptide endothelin ETA receptor antagonist. Antihypertensive

Allgemeine Beschreibung

Ambrisentan, (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid(Letairis), is a potent ETA selective endothelin antagonist that,is indicated, in the treatment of pulmonary arterial hypertension(PAH). PAH is a rare disease that if left untreated has ahigh mortality rate. In June of 2007, the FDA granted approvalof ambrisentan for once-daily treatment of PAH.Studies have shown that it improves a 6-minute walk by about30 to 60 m for patients receiving placebo.

Ambrisentan Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Ambrisentan Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 368)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806
sales@capotchem.com China 29797 60
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497
sales01@cooperate-pharm.com CHINA 1811 55
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21695 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070
product@chemlin.com.cn CHINA 3012 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32480 60
Lianyungang happen teng technology co., LTD
15950718863
wang666xt@163.com CHINA 295 58
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873
sales@chemdad.com China 39916 58

177036-94-1()Verwandte Suche:


  • BSF 208075,(+)-(2S)-2-[(4,6-DIMETHYLPYRIMIDIN-2-YL)OXY]-3-METHOXY-3,3-DIPHENYLPROPANOIC ACID
  • AMBRISENTAN
  • (aS)-a-[(4,6-Dimethyl-2-pyrimidinyl)oxy]--methoxy--phenylbenzenepropanoic Acid
  • BSF 208075
  • LU 208075
  • 2-(4,6-Dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid
  • (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid
  • (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid,bsf-208075
  • Ambrisentan Tablets
  • Benzenepropanoic acid, α-[(4,6-diMethyl-2-pyriMidinyl)oxy]-β-Methoxy-β-phenyl-, (αS)-
  • Benzenepropanoic acid, alpha-[(4,6-diMethyl-2-pyriMidinyl)oxy]-beta-Methoxy-beta-phenyl-, (alphaS)-
  • (αS)-α-[(4,6-DiMethyl-2-pyriMidinyl)oxy]-β-Methoxy-β-phenylbenzenepropanoic Acid
  • (R,S)-AMbrisentan-d5
  • AMbrisentan (BSF 208075)
  • Benzenepropanoic acid, a-[(4,6-diMethyl-2-pyriMidinyl)oxy]-b-Methoxy-b-phenyl-, (aS)-
  • LU-208075,BSF-208075
  • Ambrisentan,2-(4,6-Dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid
  • Ambrisentan, >=98%
  • (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
  • ambrisentan,CID 6918493
  • CS-135
  • Anrisentan API
  • (S)-2-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropionic Acid
  • Ambrisentan USP/EP/BP
  • ((S)-Ambrisentan)
  • AmbrisentanQ: What is Ambrisentan Q: What is the CAS Number of Ambrisentan Q: What is the storage condition of Ambrisentan Q: What are the applications of Ambrisentan
  • Ambelsentan intermediate
  • (2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoicaci
  • Ambrisentan 98% 177036-94-1
  • Ambrisentan AKSci B500
  • (R,S)-Ambrisentan
  • Benzenepropanoic acid, α-[(4,6-dimethyl-2-pyrimidinyl)oxy]-β-methoxy-β-phenyl-, (αS)-
  • 177036-94-1
  • APIs
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Other APIs
Copyright 2019 © ChemicalBook. All rights reserved